| 标题 |
Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making
|
| 网址 | |
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 求助人 | |
| 下载 |
GuanguanYaa
Lv2 求助人 发起了本次求助
PDF的下载单位、IP信息已删除
(2025-6-4)